nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2C8—Ifosfamide—testicular cancer	0.124	0.172	CbGbCtD
Levomilnacipran—CYP2C19—Ifosfamide—testicular cancer	0.104	0.144	CbGbCtD
Levomilnacipran—ABCB1—Dactinomycin—testicular cancer	0.0713	0.0983	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—testicular cancer	0.0594	0.082	CbGbCtD
Levomilnacipran—CYP3A4—Ifosfamide—testicular cancer	0.0504	0.0696	CbGbCtD
Levomilnacipran—ABCB1—Vinblastine—testicular cancer	0.0447	0.0616	CbGbCtD
Levomilnacipran—CYP2D6—Vinblastine—testicular cancer	0.0421	0.058	CbGbCtD
Levomilnacipran—ABCB1—Cisplatin—testicular cancer	0.0409	0.0565	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—testicular cancer	0.0402	0.0555	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—testicular cancer	0.0274	0.0378	CbGbCtD
Levomilnacipran—CYP3A4—Vinblastine—testicular cancer	0.0268	0.0369	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—testicular cancer	0.0266	0.0367	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—testicular cancer	0.0259	0.0357	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—testicular cancer	0.0241	0.0332	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—testicular cancer	0.0164	0.0227	CbGbCtD
Levomilnacipran—Dyspnoea—Cisplatin—testicular cancer	0.000464	0.00169	CcSEcCtD
Levomilnacipran—Skin disorder—Etoposide—testicular cancer	0.000463	0.00168	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—testicular cancer	0.000462	0.00168	CcSEcCtD
Levomilnacipran—Dry skin—Doxorubicin—testicular cancer	0.000461	0.00168	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Etoposide—testicular cancer	0.000461	0.00168	CcSEcCtD
Levomilnacipran—Angina pectoris—Epirubicin—testicular cancer	0.000458	0.00166	CcSEcCtD
Levomilnacipran—Breast disorder—Doxorubicin—testicular cancer	0.000455	0.00165	CcSEcCtD
Levomilnacipran—Anorexia—Etoposide—testicular cancer	0.000454	0.00165	CcSEcCtD
Levomilnacipran—Decreased appetite—Cisplatin—testicular cancer	0.000452	0.00164	CcSEcCtD
Levomilnacipran—Diarrhoea—Dactinomycin—testicular cancer	0.000451	0.00164	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000449	0.00163	CcSEcCtD
Levomilnacipran—Vomiting—Bleomycin—testicular cancer	0.000449	0.00163	CcSEcCtD
Levomilnacipran—Hypotension—Etoposide—testicular cancer	0.000445	0.00162	CcSEcCtD
Levomilnacipran—Rash—Bleomycin—testicular cancer	0.000445	0.00162	CcSEcCtD
Levomilnacipran—Dermatitis—Bleomycin—testicular cancer	0.000445	0.00162	CcSEcCtD
Levomilnacipran—Hypersensitivity—Ifosfamide—testicular cancer	0.000445	0.00162	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000444	0.00161	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—testicular cancer	0.000439	0.0016	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—testicular cancer	0.000439	0.0016	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—testicular cancer	0.000438	0.00159	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000437	0.00159	CcSEcCtD
Levomilnacipran—Pollakiuria—Epirubicin—testicular cancer	0.000434	0.00158	CcSEcCtD
Levomilnacipran—Asthenia—Ifosfamide—testicular cancer	0.000433	0.00157	CcSEcCtD
Levomilnacipran—Paraesthesia—Etoposide—testicular cancer	0.000428	0.00156	CcSEcCtD
Levomilnacipran—Pruritus—Ifosfamide—testicular cancer	0.000427	0.00155	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—testicular cancer	0.000427	0.00155	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—testicular cancer	0.000425	0.00155	CcSEcCtD
Levomilnacipran—Dyspnoea—Etoposide—testicular cancer	0.000425	0.00155	CcSEcCtD
Levomilnacipran—Somnolence—Etoposide—testicular cancer	0.000424	0.00154	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—testicular cancer	0.000423	0.00154	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—testicular cancer	0.000423	0.00154	CcSEcCtD
Levomilnacipran—Nausea—Bleomycin—testicular cancer	0.000419	0.00153	CcSEcCtD
Levomilnacipran—Vomiting—Dactinomycin—testicular cancer	0.000419	0.00152	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000415	0.00151	CcSEcCtD
Levomilnacipran—Rash—Dactinomycin—testicular cancer	0.000415	0.00151	CcSEcCtD
Levomilnacipran—Decreased appetite—Etoposide—testicular cancer	0.000414	0.00151	CcSEcCtD
Levomilnacipran—Diarrhoea—Ifosfamide—testicular cancer	0.000413	0.0015	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Etoposide—testicular cancer	0.000412	0.0015	CcSEcCtD
Levomilnacipran—Body temperature increased—Cisplatin—testicular cancer	0.000411	0.0015	CcSEcCtD
Levomilnacipran—Fatigue—Etoposide—testicular cancer	0.000411	0.00149	CcSEcCtD
Levomilnacipran—Constipation—Etoposide—testicular cancer	0.000408	0.00148	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—testicular cancer	0.000407	0.00148	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—testicular cancer	0.000407	0.00148	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—testicular cancer	0.000407	0.00148	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000404	0.00147	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—testicular cancer	0.000402	0.00146	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—testicular cancer	0.000402	0.00146	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—testicular cancer	0.000399	0.00145	CcSEcCtD
Levomilnacipran—Dizziness—Ifosfamide—testicular cancer	0.000399	0.00145	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—testicular cancer	0.000397	0.00144	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Epirubicin—testicular cancer	0.000396	0.00144	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—testicular cancer	0.000394	0.00143	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—testicular cancer	0.000393	0.00143	CcSEcCtD
Levomilnacipran—Nausea—Dactinomycin—testicular cancer	0.000391	0.00142	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Etoposide—testicular cancer	0.00039	0.00142	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000384	0.0014	CcSEcCtD
Levomilnacipran—Vomiting—Ifosfamide—testicular cancer	0.000384	0.0014	CcSEcCtD
Levomilnacipran—Hypersensitivity—Cisplatin—testicular cancer	0.000383	0.00139	CcSEcCtD
Levomilnacipran—Rash—Ifosfamide—testicular cancer	0.000381	0.00138	CcSEcCtD
Levomilnacipran—Dermatitis—Ifosfamide—testicular cancer	0.00038	0.00138	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—testicular cancer	0.00038	0.00138	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—testicular cancer	0.000379	0.00138	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—testicular cancer	0.000377	0.00137	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—testicular cancer	0.000377	0.00137	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—testicular cancer	0.000377	0.00137	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—testicular cancer	0.000376	0.00137	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—testicular cancer	0.000376	0.00137	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—testicular cancer	0.000374	0.00136	CcSEcCtD
Levomilnacipran—Asthenia—Cisplatin—testicular cancer	0.000373	0.00136	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—testicular cancer	0.000373	0.00136	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—testicular cancer	0.000371	0.00135	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—testicular cancer	0.00037	0.00135	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—testicular cancer	0.00037	0.00134	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—testicular cancer	0.00037	0.00134	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—testicular cancer	0.000369	0.00134	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000367	0.00133	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—testicular cancer	0.000365	0.00133	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—testicular cancer	0.000362	0.00132	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—testicular cancer	0.000361	0.00131	CcSEcCtD
Levomilnacipran—Nausea—Ifosfamide—testicular cancer	0.000358	0.0013	CcSEcCtD
Levomilnacipran—Diarrhoea—Cisplatin—testicular cancer	0.000356	0.00129	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—testicular cancer	0.000356	0.00129	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—testicular cancer	0.000352	0.00128	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—testicular cancer	0.000351	0.00128	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—testicular cancer	0.000351	0.00128	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—testicular cancer	0.00035	0.00127	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—testicular cancer	0.000349	0.00127	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—testicular cancer	0.000349	0.00127	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—testicular cancer	0.000348	0.00127	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—testicular cancer	0.000346	0.00126	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—testicular cancer	0.000344	0.00125	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—testicular cancer	0.000343	0.00125	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—testicular cancer	0.000343	0.00125	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—testicular cancer	0.000342	0.00124	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—testicular cancer	0.000342	0.00124	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—testicular cancer	0.000341	0.00124	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—testicular cancer	0.000341	0.00124	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—testicular cancer	0.000339	0.00123	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—testicular cancer	0.000337	0.00123	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—testicular cancer	0.000337	0.00123	CcSEcCtD
Levomilnacipran—Vomiting—Cisplatin—testicular cancer	0.000331	0.0012	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—testicular cancer	0.00033	0.0012	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—testicular cancer	0.000329	0.0012	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—testicular cancer	0.000329	0.0012	CcSEcCtD
Levomilnacipran—Rash—Cisplatin—testicular cancer	0.000328	0.00119	CcSEcCtD
Levomilnacipran—Dermatitis—Cisplatin—testicular cancer	0.000328	0.00119	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—testicular cancer	0.000327	0.00119	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—testicular cancer	0.000326	0.00119	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—testicular cancer	0.000325	0.00118	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—testicular cancer	0.000323	0.00117	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—testicular cancer	0.000323	0.00117	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—testicular cancer	0.000323	0.00117	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—testicular cancer	0.000321	0.00117	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—testicular cancer	0.000321	0.00117	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—testicular cancer	0.000316	0.00115	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—testicular cancer	0.000315	0.00115	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—testicular cancer	0.000314	0.00114	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—testicular cancer	0.000313	0.00114	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—testicular cancer	0.000312	0.00114	CcSEcCtD
Levomilnacipran—Nausea—Cisplatin—testicular cancer	0.000309	0.00112	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—testicular cancer	0.000309	0.00112	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—testicular cancer	0.000305	0.00111	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—testicular cancer	0.000303	0.0011	CcSEcCtD
Levomilnacipran—Vomiting—Etoposide—testicular cancer	0.000303	0.0011	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—testicular cancer	0.000303	0.0011	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—testicular cancer	0.000301	0.00109	CcSEcCtD
Levomilnacipran—Rash—Etoposide—testicular cancer	0.000301	0.00109	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—testicular cancer	0.0003	0.00109	CcSEcCtD
Levomilnacipran—Headache—Etoposide—testicular cancer	0.000299	0.00109	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—testicular cancer	0.000298	0.00109	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—testicular cancer	0.000298	0.00108	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—testicular cancer	0.000297	0.00108	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—testicular cancer	0.000297	0.00108	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000296	0.00108	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—testicular cancer	0.000294	0.00107	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—testicular cancer	0.000293	0.00107	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—testicular cancer	0.000289	0.00105	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—testicular cancer	0.000288	0.00105	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—testicular cancer	0.000285	0.00104	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—testicular cancer	0.000284	0.00103	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—testicular cancer	0.000284	0.00103	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—testicular cancer	0.000283	0.00103	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—testicular cancer	0.000283	0.00103	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—testicular cancer	0.00028	0.00102	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—testicular cancer	0.00028	0.00102	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—testicular cancer	0.000279	0.00101	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—testicular cancer	0.000278	0.00101	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—testicular cancer	0.000278	0.00101	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—testicular cancer	0.000277	0.00101	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000277	0.00101	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—testicular cancer	0.000276	0.001	CcSEcCtD
Levomilnacipran—Dry mouth—Epirubicin—testicular cancer	0.000273	0.000991	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—testicular cancer	0.000272	0.00099	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—testicular cancer	0.000272	0.000988	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—testicular cancer	0.000271	0.000986	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—testicular cancer	0.000268	0.000974	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—testicular cancer	0.000267	0.00097	CcSEcCtD
Levomilnacipran—Loss of consciousness—Doxorubicin—testicular cancer	0.000266	0.000968	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—testicular cancer	0.000265	0.000965	CcSEcCtD
Levomilnacipran—Shock—Epirubicin—testicular cancer	0.000263	0.000956	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—testicular cancer	0.000262	0.000954	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—testicular cancer	0.000262	0.000953	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—testicular cancer	0.000262	0.000951	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—testicular cancer	0.000262	0.000951	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—testicular cancer	0.000261	0.000948	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—testicular cancer	0.00026	0.000944	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Epirubicin—testicular cancer	0.000258	0.000939	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—testicular cancer	0.000258	0.000939	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—testicular cancer	0.000258	0.000938	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—testicular cancer	0.000257	0.000935	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—testicular cancer	0.000256	0.000932	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000256	0.000931	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—testicular cancer	0.000255	0.000926	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—testicular cancer	0.000255	0.000926	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—testicular cancer	0.000254	0.000923	CcSEcCtD
Levomilnacipran—Dry mouth—Doxorubicin—testicular cancer	0.000252	0.000917	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—testicular cancer	0.000251	0.000914	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—testicular cancer	0.00025	0.000908	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—testicular cancer	0.000248	0.000903	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000246	0.000896	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—testicular cancer	0.000246	0.000895	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—testicular cancer	0.000246	0.000893	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—testicular cancer	0.000243	0.000885	CcSEcCtD
Levomilnacipran—Nervous system disorder—Doxorubicin—testicular cancer	0.000242	0.000882	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—testicular cancer	0.000242	0.00088	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—testicular cancer	0.000242	0.000879	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—testicular cancer	0.000241	0.000877	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—testicular cancer	0.00024	0.000873	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—testicular cancer	0.00024	0.000873	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Doxorubicin—testicular cancer	0.000239	0.000869	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—testicular cancer	0.000238	0.000866	CcSEcCtD
Levomilnacipran—Somnolence—Epirubicin—testicular cancer	0.000238	0.000864	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—testicular cancer	0.000236	0.000857	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—testicular cancer	0.000235	0.000855	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—testicular cancer	0.000233	0.000849	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—testicular cancer	0.000232	0.000845	CcSEcCtD
Levomilnacipran—Hypotension—Doxorubicin—testicular cancer	0.000231	0.00084	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000231	0.000839	CcSEcCtD
Levomilnacipran—Fatigue—Epirubicin—testicular cancer	0.00023	0.000838	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—testicular cancer	0.000228	0.000831	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—testicular cancer	0.000227	0.000825	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—testicular cancer	0.000226	0.000821	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—testicular cancer	0.000226	0.000821	CcSEcCtD
Levomilnacipran—Insomnia—Doxorubicin—testicular cancer	0.000224	0.000813	CcSEcCtD
Levomilnacipran—Paraesthesia—Doxorubicin—testicular cancer	0.000222	0.000807	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—testicular cancer	0.00022	0.000802	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—testicular cancer	0.00022	0.000799	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Epirubicin—testicular cancer	0.000218	0.000795	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—testicular cancer	0.000218	0.000791	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—testicular cancer	0.000215	0.000782	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000213	0.000776	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—testicular cancer	0.000213	0.000775	CcSEcCtD
Levomilnacipran—Urticaria—Epirubicin—testicular cancer	0.000212	0.000772	CcSEcCtD
Levomilnacipran—Constipation—Doxorubicin—testicular cancer	0.000211	0.000769	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—testicular cancer	0.000211	0.000768	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—testicular cancer	0.000211	0.000768	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—testicular cancer	0.00021	0.000765	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—testicular cancer	0.000205	0.000745	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000202	0.000735	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—testicular cancer	0.000202	0.000735	CcSEcCtD
Levomilnacipran—Hypersensitivity—Epirubicin—testicular cancer	0.000197	0.000716	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—testicular cancer	0.000196	0.000714	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—testicular cancer	0.000195	0.000711	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—testicular cancer	0.000195	0.000711	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—testicular cancer	0.000195	0.00071	CcSEcCtD
Levomilnacipran—Asthenia—Epirubicin—testicular cancer	0.000192	0.000697	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—testicular cancer	0.000189	0.000687	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—testicular cancer	0.000189	0.000687	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—testicular cancer	0.000183	0.000665	CcSEcCtD
Levomilnacipran—Hypersensitivity—Doxorubicin—testicular cancer	0.000182	0.000662	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—testicular cancer	0.000182	0.00066	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—testicular cancer	0.00018	0.000655	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—testicular cancer	0.00018	0.000654	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—testicular cancer	0.000179	0.00065	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—testicular cancer	0.000177	0.000645	CcSEcCtD
Levomilnacipran—Dizziness—Epirubicin—testicular cancer	0.000177	0.000643	CcSEcCtD
Levomilnacipran—Pruritus—Doxorubicin—testicular cancer	0.000175	0.000636	CcSEcCtD
Levomilnacipran—Vomiting—Epirubicin—testicular cancer	0.00017	0.000618	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—testicular cancer	0.00017	0.000617	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—testicular cancer	0.000169	0.000615	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—testicular cancer	0.000168	0.000613	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—testicular cancer	0.000168	0.000612	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—testicular cancer	0.000167	0.000609	CcSEcCtD
Levomilnacipran—Dizziness—Doxorubicin—testicular cancer	0.000163	0.000595	CcSEcCtD
Levomilnacipran—Nausea—Epirubicin—testicular cancer	0.000159	0.000577	CcSEcCtD
Levomilnacipran—Vomiting—Doxorubicin—testicular cancer	0.000157	0.000572	CcSEcCtD
Levomilnacipran—Rash—Doxorubicin—testicular cancer	0.000156	0.000567	CcSEcCtD
Levomilnacipran—Dermatitis—Doxorubicin—testicular cancer	0.000156	0.000566	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—testicular cancer	0.000155	0.000563	CcSEcCtD
Levomilnacipran—Nausea—Doxorubicin—testicular cancer	0.000147	0.000534	CcSEcCtD
